Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Aurora Cannabis vs. Scotts Miracle-Gro Company

By David Jagielski – Updated Feb 3, 2020 at 2:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Which stock is a better option for investors who want exposure to the high-growth cannabis industry?

Cannabis investments have proven to be very risky over the past year. With Aurora Cannabis (ACB -2.40%) and Scotts Miracle-Gro (SMG -3.10%), investors have two very different ways they can gain exposure to the industry. Are you better off investing in a cannabis producer with global reach, or a hydroponics company that has more of an indirect interest in the industry? Let's find out.

Do Aurora's rewards outweigh its risks?

Aurora has a presence in more than two dozen countries across the world, and it's an appealing long-term investment if you expect cannabis legalization to continue its progress around the globe. The potential is significant: By 2025, Grand View Research projects that the legal marijuana market will grow to $66.3 billion, growing at a compounded annual growth rate of 23.9%. It's one of the reasons Aurora appeals to investors, because the company has ambitions that go beyond North America.

The problem is that in the near future, there are many headwinds that could impact its growth and overall profitability. From vaping concerns weighing on the cannabis 2.0 market to a relatively low number of retailers open in Canada some 15 months after the country legalized recreational marijuana, there are many challenges still ahead for the industry.

Cannabis plant.

Image source: Getty Images.

With Aurora already falling out of favor with many investors for a lack of profitability and disappointing sales numbers, there's little reason for much bullishness in the short term. If Aurora can weather the storm, it could have significant growth opportunities ahead. However, that could still be many years away, and the industry will likely look much different than it does today, leaving many questions about what Aurora's growth prospects may look like.

Is there enough growth with Scotts?

Scotts is definitely the safer cannabis play given that the company isn't a producer of marijuana and it doesn't have to worry about quality or which direction pot prices are going. Instead, the plant-growth specialist is effectively a supplier for the industry, and as long as more people are growing marijuana, there will be demand for its products.

The company's growth has been strong thus far, with sales in fiscal 2019 rising 18.5% from the prior year -- much of that coming from the Hawthorne growing company, which provides supplies for hydroponic gardening (growing plants without soil). Revenue for the Hawthorne segment actually rose 94% and the overall growth was weighed down by the company's U.S. consumer segment, which focuses on the lawn and garden business. That segment of the business grew at a much more modest rate of 8% from the prior year.

With such a strong performance in 2019 from Hawthorne, Scotts is expecting 2020's sales for that segment to be between just 12% and 15%. It's a modest expectation and one that could highlight the limited growth that Scotts may achieve in light of it not selling cannabis or being directly involved in the industry. 

The company is already off to a strong start, as it recently reported first-quarter results that beat expectations. Sales were up 23% and Hawthorne's top line increased 41% year over year. Scotts' quarterly loss was also better than what analysts were expecting.

Which stock is the better buy?

Both stocks have a lot of potential to benefit from the cannabis industry's growth over the years. However, the advantage goes to Scotts. The company is profitable, it can benefit from the growth of the U.S. cannabis market (whereas Aurora can only sell hemp-derived cannabidiol products since pot remains illegal at the federal level in the U.S.), and it also trades at a more reasonable multiple. Selling at around 15 times earnings and just 2 times its sales, Scotts has a cheaper valuation than Aurora, which investors value at 10 times its top line, and which has no profit to even generate a price-to-earnings multiple.

And given how volatile the industry has been of late, with the Horizons Marijuana Life Sciences ETF losing more than 40% of its value in six months, now is a time that investors should be looking for safer investment options. While both stocks have great growth potential, Scotts is a more balanced and value-oriented investment, making it the better overall buy today.

 

David Jagielski owns shares of Scotts Miracle-Gro. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Scotts Miracle-Gro Company Stock Quote
The Scotts Miracle-Gro Company
SMG
$42.75 (-3.10%) $-1.37
Aurora Cannabis Stock Quote
Aurora Cannabis
ACB
$1.22 (-2.40%) $0.03
Horizons Marijuana Life Sciences Index ETF Stock Quote
Horizons Marijuana Life Sciences Index ETF
HMLSF
$4.45 (-3.28%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.